The Food and Drug Administration has extended the review period for sparsentan in focal segmental glomerulosclerosis (FSGS).

Please provide your email address to receive an email when new articles are posted on . Researchers identified functionally relevant risk factors for pediatric primary focal segmental ...

The timeline extension comes on the heels of the FDA requesting additional information to assess Filspari’s clinical benefit.

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder that affects children and adults, and can lead to kidney failure. New findings from a team led by the University of Minnesota ...

EXTON, Pa., March 22, 2021 /PRNewswire/ — Glomerular diseases, including IgA nephropathy (IgAN), focal segmental glomerulosclerosis (FSGS), and Alport Syndrome, among others, together amount to the ...

Please provide your email address to receive an email when new articles are posted on . Among patients with focal segmental glomerulosclerosis, immunosuppressant therapy reduced proteinuria but showed ...

Travere Therapeutics recently reported that the FDA has extended its review of the supplemental New Drug Application for ...

Focal segmental glomerulosclerosis (FSGS) still lacks an FDA-approved therapy, but late-breaking post hoc results from the phase III DUPLEX trial -- presented at the National Kidney Foundation Spring ...

The most important message is that FSGS is a lesion and not a disease. The finding of an FSGS lesion is the start of an exploratory process leading to a diagnosis and not an end in itself. We propose ...